GURU.Markets stock price, segment price, and overall market index valuation
The company's share price Neumora Therapeutics
Neumora Therapeutics is a biotech company using data science to develop drugs for brain diseases. Its stock price is a bet that its technological approach will lead to breakthroughs in this complex field of medicine.
Share prices of companies in the market segment - Neuro
Neumora Therapeutics is a biopharmaceutical company using data science to develop new treatments for brain diseases. We've categorized it under "Neurology," and the chart below shows how the market values innovative approaches in this complex and investment-intensive field of medicine.
Broad Market Index - GURU.Markets
Neumora Therapeutics is a biopharmaceutical company using data science to develop new treatments for brain diseases. We've categorized it under "Neurology," and the chart below shows how the market values innovative approaches in this complex and investment-intensive field of medicine.
Change in the price of a company, segment, and market as a whole per day
NMRA - Daily change in the company's share price Neumora Therapeutics
Neumora, a company focused on brain diseases, is highly volatile. change_co tracks market reactions to research data. This metric is fundamental to building complex biotech risk assessment models on System.GURU.Markets.
Daily change in the price of a set of shares in a market segment - Neuro
Neumora Therapeutics, Inc. is a biotech company. This chart highlights the extreme volatility of the sector. Comparison with NMRA, which focuses on CNS diseases, helps to assess it as a high-risk, clinical-data-driven asset.
Daily change in the price of a broad market stock, index - GURU.Markets
Neumora is a biopharmaceutical company specializing in drugs for the treatment of brain diseases. Neuroscience is a risky field of research. The chart below illustrates the high volatility typical of the biotech sector, reflecting the stakes associated with Neumora's developments.
Dynamics of market capitalization of the company, segment and the market as a whole over 12 months
Annual dynamics of the company's market capitalization Neumora Therapeutics
Neumora Therapeutics' year-to-date performance reflects its ambitious attempt to revolutionize the treatment of brain diseases through precision medicine. Its 12-month market cap depends on progress in its extensive clinical pipeline. Its partnership with Amgen is a key validation of the potential of its approach to developing new neurotherapeutics.
Annual dynamics of market capitalization of the market segment - Neuro
Neumora Therapeutics, a recent IPO, is a biotech company using data analytics to develop drugs for brain diseases. This chart shows how the market views its innovative, data-driven approach to this complex area of medicine compared to the traditional biotech sector.
Annual dynamics of market capitalization of broad market stocks, index - GURU.Markets
Neumora is a biotech company whose fate since its IPO has depended on the success of its drugs for treating nervous system disorders. Its stock price is completely disconnected from economic cycles. The chart reflects scientific events—news about clinical trials—not macroeconomic data.
Dynamics of market capitalization of the company, segment and the market as a whole for the month
Monthly dynamics of the company's market capitalization Neumora Therapeutics
Neumora's performance as a biopharmaceutical company will be speculative. Monthly fluctuations on the chart will reflect not revenue, but rather news about the progress of clinical trials of its drugs for the treatment of neurological and psychiatric disorders, which will determine its future.
Monthly dynamics of market capitalization of the market segment - Neuro
Neumora Therapeutics is a biotech company that uses big data analysis to develop a new generation of drugs for brain diseases. It strives for precision approaches in psychiatry and neurology. The chart below reflects the general sentiment in the neuroscience sector, where Neumora offers a new approach.
Monthly dynamics of market capitalization of broad market stocks, index - GURU.Markets
Neumora Therapeutics is a biotech company focused on treating brain diseases. Its stock is a classic venture capital bet. Its performance depends entirely on the success or failure of clinical trials and has no connection to broader market movements.
Dynamics of market capitalization of the company, segment and the market as a whole for the week
Weekly dynamics of the company's market capitalization Neumora Therapeutics
Shares of Neumora Therapeutics, a biopharmaceutical company focused on brain diseases, are extremely volatile. Weekly price movements depend entirely on news about the progress of clinical trials of their drug candidates. The chart below illustrates how short-term scientific developments and investor expectations shape value in innovative medicine.
Weekly dynamics of market capitalization of the market segment - Neuro
How does Neumora Therapeutics' performance compare to the broader biotech sector? This chart compares the weekly stock price movements of this brain-focused company with the overall trend. This helps us understand whether its movement is the result of a unique scientific event or a reflection of overall investor sentiment.
Weekly dynamics of market capitalization of stocks of the broad market, index - GURU.Markets
Neumora Therapeutics is a biotech company using big data to develop drugs for brain diseases. This chart compares its weekly performance to the market, showing how its stock, like other biotechs, is driven by clinical trial news rather than general market trends.
Market capitalization of the company, segment and market as a whole
NMRA - Market capitalization of the company Neumora Therapeutics
Neumora Therapeutics' market capitalization represents a massive bet on a new approach to treating brain diseases. Backed by major investors, the company uses big data to develop targeted drugs. Its price reflects the market's belief that this approach could finally lead to a breakthrough in neuroscience.
NMRA - Share of the company's market capitalization Neumora Therapeutics within the market segment - Neuro
Neumora Therapeutics is a biopharmaceutical company whose market share is based on its approach to precision medicine in neurology. Its market capitalization reflects its goal of developing targeted therapies for brain diseases.
Market capitalization of the market segment - Neuro
The chart below is a barometer of the biotech sector using AI and big data to develop drugs for the central nervous system. Neumora Therapeutics is one of the most ambitious new players. The dynamics on the chart reflect investors' belief that this new approach can crack the code of brain diseases.
Market capitalization of all companies included in a broad market index - GURU.Markets
This chart visualizes the hope for a breakthrough in the treatment of depression and schizophrenia. Neumora Therapeutics' market cap is a bet on its precision medicine platform for brain diseases. The line shows how this new data-driven approach to psychiatry is generating a huge potential share of the global economy.
Book value capitalization of the company, segment and market as a whole
NMRA - Book value capitalization of the company Neumora Therapeutics
Neumora Therapeutics' book value represents its scientific capital. The chart below reflects the value of its precision neuroscience platform and its pipeline of developments targeting brain diseases. The line's growth signals advances in research, which is the biotech company's core asset.
NMRA - Share of the company's book capitalization Neumora Therapeutics within the market segment - Neuro
For Neumora, a biopharmaceutical company focused on brain diseases, its tangible assets are its cutting-edge laboratories and data analytics platform. The chart shows the company's share of this high-tech scientific infrastructure, which forms the physical foundation for precision neuroscience.
Market segment balance sheet capitalization - Neuro
Below you can see the overall book value of the pharmaceutical sector. Compared to this, Neumora, which develops drugs for brain diseases, looks like a "lightweight." Its value lies in its approach to precision medicine and data, not in its ownership of large manufacturing plants.
Book value of all companies included in the broad market index - GURU.Markets
Neumora Therapeutics is a biotech company using big data to develop new drugs for brain diseases. The company's assets are not factories, but rather an analytics platform and a pipeline of developments. Their balance sheet represents the value of a new approach to drug development in one of the most complex areas of medicine.
The ratio of market capitalization to book capitalization of a company, segment, and the market as a whole
Market capitalization to book capitalization ratio - Neumora Therapeutics
Neumora's balance sheet is its cash and scientific platform. Its market cap is a bet on its novel, data-driven approach to treating brain diseases. The MvsBCap_Co chart shows the premium investors are paying for "hope" and a "new method" in a highly complex field of medicine.
Market to book capitalization ratio in a market segment - Neuro
Neumora Therapeutics is a biotech company using big data and AI to develop drugs for brain diseases. Its value lies in its innovative approach. The chart shows the speculative market valuation of its platform, which investors hope will accelerate the discovery of new treatments.
Market to book capitalization ratio for the market as a whole
Neumora Therapeutics is a biotech company using a precision medicine approach to develop drugs for brain diseases. Its value lies in its scientific platform and data. This chart illustrates why investors are willing to pay a premium for innovative approaches to treating complex diseases such as depression and schizophrenia.
Debts of the company, segment and market as a whole
NMRA - Company debts Neumora Therapeutics
Neumora Therapeutics, a biopharmaceutical company focused on brain diseases, is using debt to finance its innovative approach. This chart shows how the company is raising capital to conduct clinical trials using its precision medicine platform. Debt here represents an investment in a new approach to neuroscience drug development.
Market segment debts - Neuro
Neumora Therapeutics is a biotech company using a precision medicine approach to develop drugs for brain diseases, one of the most complex areas in medicine. This chart shows how the company funds its extensive and capital-intensive research, striving to achieve breakthroughs in the treatment of neurological and psychiatric disorders.
Market debt in general
Debt to book value of the company, segment and market as a whole
The company's debt to book capitalization ratio Neumora Therapeutics
Neumora Therapeutics is a biotech company focused on developing drugs to treat brain diseases. This chart shows its dependence on external capital. In one of the most complex fields of medicine, where research failures are the norm, high debt poses a huge risk, depending on a scientific breakthrough.
Market segment debt to market segment book capitalization - Neuro
Neumora Therapeutics is a biotech company using big data and machine learning to develop drugs for brain diseases. This approach is innovative but capital-intensive. The chart shows how the company's debt load for R&D funding compares to the overall biotech market capitalization.
Debt to book value of all companies in the market
Neumora Therapeutics (NMRA) is a biopharmaceutical company using data science to develop treatments for brain diseases. This approach represents an innovative approach in neuroscience. This chart shows the overall level of debt in the economy. It helps explain why companies like Neumora rely on equity rather than debt during the research phase.
P/E of the company, segment and market as a whole
P/E - Neumora Therapeutics
For Neumora Therapeutics, a biotech company using big data to develop drugs for brain diseases, this chart is a measure of faith in its innovative approach. There is no P/E ratio. The valuation is based on the potential of its platform to find new targets for the treatment of depression and schizophrenia, not on current revenue.
P/E of the market segment - Neuro
This industry metric represents the average P/E for biotech companies working in neuroscience. For Neumora, with its innovative, data-driven approach, it serves as a backdrop. It reflects the overall level of investor confidence in this complex field, providing context for Neumora's valuation, which is a bet on its scientific platform.
P/E of the market as a whole
Neumora Therapeutics is a biopharmaceutical company using precision medicine to develop treatments for brain diseases. The company uses big data analysis to identify biomarkers and tailor treatments. This risk appetite chart helps understand how investors evaluate innovative approaches in neuroscience.
Future P/E of the company, segment and market as a whole
Future (projected) P/E of the company Neumora Therapeutics
Neumora Therapeutics is a biopharmaceutical company using precision medicine to develop drugs for brain disorders. This graph reflects expectations for this new approach to treating mental and neurological disorders. The assessment depends on the success of its data analytics platform and the results of clinical trials of its candidates.
%20P%2FE%20Neumora%20Therapeutics&width=1500&height=450&colorIndex=35&filename=GURU_Markets_-_Chart-of-the-companys-future-projected-PE-Neumora-Therapeutics&v=1772655872278 "Chart of the company's future (projected) P/E Neumora Therapeutics")
Future (projected) P/E of the market segment - Neuro
Neumora Therapeutics is a biotech company using big data and machine learning to develop drugs for brain diseases. This chart reflects the company's long-term profitability expectations and demonstrates how highly the market values their innovative approach to finding new treatments for depression, schizophrenia, and other disorders.
%20P%2FE%20graph%20of%20the%20market%20segment%20-%20Neuro&width=1500&height=450&colorIndex=36&filename=GURU_Markets_-_Future-projected-PE-graph-of-the-market-segment-Neuro&v=1772655872284 "Future (projected) P/E graph of the market segment - Neuro")
Future (projected) P/E of the market as a whole
Neumora Therapeutics is a biotech company using big data to develop drugs for brain diseases. Its approach is based on precision medicine. This market expectations chart reflects investor appetite for risky but potentially revolutionary approaches in pharmaceuticals. Market optimism facilitates capital raising.
%20P%2FE%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=37&filename=GURU_Markets_-_Chart-of-the-future-projected-PE-of-the-market-as-a-whole&v=1772655872300 "Chart of the future (projected) P/E of the market as a whole")
Profit of the company, segment and market as a whole
Company profit Neumora Therapeutics
Neumora Therapeutics is a biotech company that uses big data and artificial intelligence to develop drugs for the treatment of brain diseases. It strives to apply precision approaches to complex mental and neurological disorders. Its financial results reflect its investment in this innovative R&D platform.
Profit of companies in the market segment - Neuro
Amgen-backed Neumora Therapeutics is using big data and AI to develop drugs for brain diseases. It's a new approach to one of the most complex areas of medicine. This biotech chart shows how the integration of technology and biology is shaping the future of R&D, with investments in data platforms driving the potential for future breakthroughs.
Overall market profit
Neumora Therapeutics is a biotech company using big data and artificial intelligence to develop drugs for brain diseases. Its approach is innovative. The company's success depends on the effectiveness of its platform and clinical trial results, not on the macroeconomic cycles reflected in this chart.
Future (predicted) profit of the company, segment and market as a whole
Future (projected) profit of the company Neumora Therapeutics
Neumora Therapeutics is a biotechnology company using a precision medicine approach to developing drugs for the treatment of brain diseases. This schedule reflects expectations, which depend on the success of its clinical programs. The ability to identify the right patients for its therapies is a key element of its strategy and forecasts.
%20profit%20of%20the%20company%20Neumora%20Therapeutics&width=1500&height=450&colorIndex=41&filename=GURU_Markets_-_Graph-of-future-projected-profit-of-the-company-Neumora-Therapeutics&v=1772655872358 "Graph of future (projected) profit of the company Neumora Therapeutics")
Future (predicted) profit of companies in the market segment - Neuro
Neumora Therapeutics is a biotech company using big data and machine learning to develop precision drugs for brain diseases. This chart shows the revenue forecast for the entire neuropharmaceutical sector. It reflects expectations for breakthroughs in the treatment of psychiatric and neurological disorders. This context is important for assessing Neumora's innovative approach.
%20profits%20of%20companies%20in%20a%20market%20segment%20-%20Neuro&width=1500&height=450&colorIndex=42&filename=GURU_Markets_-_Graph-of-future-predicted-profits-of-companies-in-a-market-segment-Neuro&v=1772655872403 "Graph of future (predicted) profits of companies in a market segment - Neuro")
Future (predicted) profit of the market as a whole
Neumora Therapeutics is a biotech company using data science to develop drugs for brain diseases. Its success depends on the effectiveness of its platform and trial results. The overall economic climate, reflected in the graph, influences the company through the availability of funding for long-term and risky clinical trials in neurology.
%20profits%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=43&filename=GURU_Markets_-_Chart-of-future-predicted-profits-of-the-market-as-a-whole&v=1772655872412 "Chart of future (predicted) profits of the market as a whole")
P/S of the company, segment and market as a whole
P/S - Neumora Therapeutics
Neumora Therapeutics is a biotech company using a precision medicine approach to develop drugs for brain diseases. It uses data analysis to identify patient groups that may benefit from its therapy. This chart shows how investors view its innovative approach to treating depression and other complex mental disorders.
P/S market segment - Neuro
Neumora Therapeutics is a clinical-stage biopharmaceutical company using a data-driven approach and precision medicine to develop new treatments for brain diseases. This chart shows the average valuation in the sector, helping to understand how the market views Neumora's innovative, data-driven approach to neuroscience.
P/S of the market as a whole
Neumora Therapeutics is a clinical-stage biotech company using a data-driven approach to developing new treatments for brain disorders such as depression and schizophrenia. This market valuation chart helps understand the premium investors are paying for the biotech's potentially breakthrough, yet risky, revenue.
Future P/S of the company, segment and market as a whole
Future (projected) P/S of the company Neumora Therapeutics
Neumora Therapeutics is a biotech company using data analytics to develop drugs for brain diseases. Although it has no revenue, it is valued based on its potential. This chart reflects investors' faith in its innovative approach and ability to succeed in the complex field of neuroscience.
%20P%2FS%20Neumora%20Therapeutics&width=1500&height=450&colorIndex=47&filename=GURU_Markets_-_The-graph-of-the-companys-future-projected-PS-Neumora-Therapeutics&v=1772655872446 "The graph of the company's future (projected) P/S Neumora Therapeutics")
Future (projected) P/S of the market segment - Neuro
Neumora Therapeutics is a biopharmaceutical company using a precision medicine approach to developing treatments for brain diseases. This chart compares market expectations for its future revenue with other neuroscience companies. The valuation reflects investor confidence in its data platform and its pipeline of clinical candidates.
%20P%2FS%20market%20segment%20graph%20-%20Neuro&width=1500&height=450&colorIndex=48&filename=GURU_Markets_-_Future-projected-PS-market-segment-graph-Neuro&v=1772655872460 "Future (projected) P/S market segment graph - Neuro")
Future (projected) P/S of the market as a whole
Neumora Therapeutics is a biotech company using big data to develop drugs for brain diseases. It's a novel approach to a complex problem. Market optimism, evident in this chart, helps companies like this attract the capital needed to test innovative hypotheses and conduct expensive clinical trials.
%20P%2FS%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=49&filename=GURU_Markets_-_Chart-of-the-future-projected-PS-of-the-market-as-a-whole&v=1772655872468 "Chart of the future (projected) P/S of the market as a whole")
Sales of the company, segment and market as a whole
Company sales Neumora Therapeutics
Neumora Therapeutics is a biotech company using precision medicine to develop drugs for the treatment of brain diseases. Currently in the clinical stage, its revenue comes from collaborations with major pharmaceutical partners. The chart reflects the funding supporting its innovative approach to neuroscience.
Sales of companies in the market segment - Neuro
Neumora Therapeutics is a biotech company using advanced data analytics to develop drugs for brain diseases. Its approach is focused on precisely identifying patient groups that can benefit from its therapy. Revenue is generated from partnerships. This graph highlights the renewed interest in neuroscience, where precision medicine like Neumora's approach offers new hope.
Overall market sales
Neumora Therapeutics is a biotech company using big data and AI to develop drugs for brain diseases. Its success depends on breakthroughs in research. The connection to this graph is indirect: the overall state of the economy affects the availability of capital to fund ambitious and long-term neuroscience projects.
Future sales volume of the company, segment and market as a whole
Future (projected) sales of the company Neumora Therapeutics
Neumora Therapeutics is a biotech company using a precision medicine approach to develop drugs for brain diseases. The company aims to identify biomarkers to tailor treatments to specific patient groups. This chart reflects analysts' confidence in its scientific platform and the potential to create breakthrough drugs in psychiatry and neurology.
%20sales%20of%20the%20company%20Neumora%20Therapeutics&width=1500&height=450&colorIndex=53&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-the-company-Neumora-Therapeutics&v=1772655872560 "Schedule of future (projected) sales of the company Neumora Therapeutics")
Future (projected) sales of companies in the market segment - Neuro
Neumora Therapeutics is a biotech company using advanced data analytics to develop new treatments for brain diseases. This chart shows the overall outlook for the neuroscience sector, assessing whether the company's innovative approach to target discovery can accelerate drug development in one of the most challenging areas of medicine.
%20sales%20of%20companies%20in%20the%20market%20segment%20-%20Neuro&width=1500&height=450&colorIndex=54&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-companies-in-the-market-segment-Neuro&v=1772655872583 "Schedule of future (projected) sales of companies in the market segment - Neuro")
Future (projected) sales of the market as a whole
Neumora Therapeutics is a biotech company using data science to develop drugs for brain diseases. This chart, reflecting the investment climate in biotech, is critically important. Developing drugs in this complex field requires significant capital, and Neumora's ability to attract funding depends on overall economic confidence.
%20sales%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=55&filename=GURU_Markets_-_Schedule-of-future-predicted-sales-of-the-market-as-a-whole&v=1772655872600 "Schedule of future (predicted) sales of the market as a whole")
Marginality of the company, segment and market as a whole
Company marginality Neumora Therapeutics
Neumora Therapeutics is a biotech company focused on developing new treatments for brain diseases. It uses a precision medicine approach to create targeted therapies. This chart illustrates the significant investment in research and development required to achieve breakthroughs in one of the most challenging areas of medicine.
Market segment marginality - Neuro
Neumora Therapeutics is a biotech company that uses a precision medicine approach to develop drugs for brain diseases. They use data analysis to select the right treatment for the right patient group. This chart reflects their investment in this innovative R&D platform, which is focused on solving complex problems in neurology.
Market marginality as a whole
Neumora Therapeutics is a biotech company using advanced data analytics to develop drugs for brain diseases. The big picture of profitability is irrelevant to them. Their strategy is a more precise approach to neuroscience. Success depends on whether their platform proves its ability to create effective drugs in this complex field.
Employees in the company, segment and market as a whole
Number of employees in the company Neumora Therapeutics
Neumora Therapeutics is a neuroscience company using big data analytics to develop targeted drugs for brain diseases. This graph shows the team, which includes neuroscientists and data scientists. The growth of the team reflects the progress of its clinical programs and the sophistication of its R&D platform.
Share of the company's employees Neumora Therapeutics within the market segment - Neuro
Neumora Therapeutics is a biopharmaceutical company using a precision approach to developing drugs for brain diseases. This chart shows the percentage of leading scientists in neuroscience and data analysis that the company employs. This is a testament to its innovative strategy and team's commitment to changing the treatment paradigm for mental and neurological disorders.
Number of employees in the market segment - Neuro
Neumora Therapeutics is a biotechnology company using precision medicine to develop drugs for brain diseases. This chart shows the growth of employment in the neuroscience research sector. The increase in scientists reflects new approaches to treating mental and neurological disorders based on data analysis and biomarker identification.
Number of employees in the market as a whole
Neumora Therapeutics is a biotech company using advanced data analytics to develop precision drugs for brain diseases. It represents a new approach to neuroscience. In this chart illustrating the overall job market, companies like Neumora are at the intersection of biotech and IT, creating demand for data scientists, geneticists, and neuroscientists.
Market capitalization per employee (in thousands of dollars) of the company, segment, and market as a whole
Market capitalization per employee (in thousands of dollars) of the company Neumora Therapeutics (NMRA)
Neumora Therapeutics, Inc. is a biopharmaceutical company specializing in brain diseases. Its value is determined by the potential of its scientific developments. This chart illustrates a model with a very high market capitalization per employee. Investors are betting that a small team of scientists will be able to create breakthrough drugs for the treatment of depression, schizophrenia, and other disorders.
%20of%20the%20company%20Neumora%20Therapeutics%20(NMRA)&width=1500&height=450&colorIndex=63&filename=GURU_Markets_-_Chart-of-market-capitalization-per-employee-in-thousands-of-dollars-of-the-company-Neumora-Therapeutics-NMRA&v=1772655872711 "Chart of market capitalization per employee (in thousands of dollars) of the company Neumora Therapeutics (NMRA)")
Market capitalization per employee (in thousands of dollars) in the market segment - Neuro
Monogram Technologies is developing a robotic system for orthopedic surgery using 3D printing. This represents the future of personalized medicine. The chart shows how the market perceives the potential of this breakthrough technology. The cost per employee reflects investor expectations for the ability of this small team to transform the multi-billion dollar implant market.
%20by%20market%20segment%20-%20Neuro&width=1500&height=450&colorIndex=64&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-by-market-segment-Neuro&v=1772655872744 "Market capitalization per employee (in thousands of dollars) by market segment - Neuro")
Market capitalization per employee (in thousands of dollars) for the overall market
Neumora Therapeutics is a biotech company using big data analytics to develop new drugs for brain diseases. This chart shows a high market value per employee, reflecting the value of their innovative approach, which can accelerate and reduce the cost of drug development in the complex field of neurology.
%20for%20the%20overall%20market&width=1500&height=450&colorIndex=65&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-for-the-overall-market&v=1772655872759 "Market capitalization per employee (in thousands of dollars) for the overall market")
Profit per employee (in thousands of dollars) for the company, segment, and market as a whole
Profit per employee (in thousands of dollars) of the company Neumora Therapeutics (NMRA)
Neumora Therapeutics (NMRA) is a biopharmaceutical company using data science and AI to develop drugs for brain diseases. It's R&D powered by technology. This chart shows the "cost" of their R&D platform—the negative profit (expense) per employee (scientist, data scientist).
%20Chart%20Neumora%20Therapeutics%20(NMRA)&width=1500&height=450&colorIndex=66&filename=GURU_Markets_-_Company-Profit-Per-Employee-in-thousands-of-dollars-Chart-Neumora-Therapeutics-NMRA&v=1772655872769 "Company Profit Per Employee (in thousands of dollars) Chart Neumora Therapeutics (NMRA)")
Profit per employee (in thousands of dollars) in the market segment - Neuro
Neumora Therapeutics uses a precision medicine approach to treating brain diseases. They use data analysis and biomarkers to select therapies. This chart demonstrates the benchmark for biotech staff performance. It is important for assessing how effectively Neumora's scientific team is implementing its data-driven approach.
%20in%20the%20market%20segment%20-%20Neuro&width=1500&height=450&colorIndex=67&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-in-the-market-segment-Neuro&v=1772655872784 "Chart of profit per employee (in thousands of dollars) in the market segment - Neuro")
Profit per employee (in thousands of dollars) for the market as a whole
Neumora Therapeutics is a biotech focused on developing drugs for brain diseases using a precision medicine approach (data-driven therapy selection). This is a sophisticated R&D company. The chart shows the amount of capital (negative profit) spent per employee to collect data and conduct clinical trials in this complex field.
%20for%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=68&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-for-the-market-as-a-whole&v=1772655872797 "Chart of profit per employee (in thousands of dollars) for the market as a whole")
Sales to employees of the company, segment and market as a whole
Sales per company employee Neumora Therapeutics (NMRA)
Neumora Therapeutics is a biotech company using data science to develop new drugs for brain diseases. This chart reflects its scientific focus. Zero revenue per employee is the norm for a clinical-stage company investing in breakthrough research to create a new generation of neuroscience drugs.
&width=1500&height=450&colorIndex=69&filename=GURU_Markets_-_Sales-chart-per-company-employee-Neumora-Therapeutics-NMRA&v=1772655872803 "Sales chart per company employee Neumora Therapeutics (NMRA)")
Sales per employee in the market segment - Neuro
Neumora (NMRA) is a biotech company using data science and AI to develop next-generation therapeutics for brain (CNS) diseases. This chart shows how much revenue (from partnerships) each employee (scientist, data scientist) generates. It's an indicator of the productivity of their AI-powered R&D platform.
Sales per employee for the market as a whole
Neumora Therapeutics is a biotech company using AI to discover new treatments for brain diseases (depression, neurodegeneration). It is a clinical-stage R&D company with no revenue. This graph (close to zero) reflects investments in science and technology: a staff of scientists and data analysts is working on developing a pipeline of drugs.
Short shares by company, segment and market as a whole
Shares shorted by company Neumora Therapeutics (NMRA)
Neumora Therapeutics is a biotech company using data science to develop new treatments for brain diseases. This chart shows bearish bets. The shorts are driven by the fact that neuroscience is one of the most challenging areas for drug development, with a high failure rate in clinical trials.
&width=1500&height=450&colorIndex=72&filename=GURU_Markets_-_Short-Shares-Chart-for-the-Company-Neumora-Therapeutics-NMRA&v=1772655872845 "Short Shares Chart for the Company Neumora Therapeutics (NMRA)")
Shares shorted by market segment - Neuro
Neumora Therapeutics (NMRA) is a biotech company focused on developing drugs to treat brain disorders (depression, schizophrenia). This chart shows the bets against the entire biotech sector. The rising bets against the industry reflect deep investor skepticism about the success of treating complex mental disorders after decades of failure.
Shares shorted by the overall market
Neumora Therapeutics (NMRA) is a clinical-stage biotech focused on developing drugs for brain diseases. This is one of the most complex areas in medicine. This market fear chart shows when investors flee the riskiest sectors. NMRA shares, operating in a highly complex field, are falling sharply.
RSI 14 indicator for a company, segment, and market as a whole
The company's RSI 14 indicator Neumora Therapeutics (NMRA)
Neumora Therapeutics is a clinical-stage biotech focused on brain diseases. Shares are sensitive to R&D news. This chart can surge above 70 on positive trial data. Oversold territory (<30) often reflects setbacks or concerns about funding or competition.
&width=1500&height=450&colorIndex=75&filename=GURU_Markets_-_RSI-14-indicator-chart-for-the-companys-stock-Neumora-Therapeutics-NMRA&v=1772655872879 "RSI 14 indicator chart for the company's stock Neumora Therapeutics (NMRA)")
RSI 14 Market Segment - Neuro
Neumora Therapeutics is a biotech company using a precision approach to treat complex brain disorders such as depression and schizophrenia. This sector is highly dependent on clinical trial data. This chart shows the overall momentum in the neuro biotech segment. It helps distinguish the reaction to the NMRA news from general euphoria or industry-wide panic.
RSI 14 for the overall market
Neumora Therapeutics (NMRA) is a biotech company. Like everything in its sector, it's critically dependent on this schedule. Market euphoria offers the potential to easily raise hundreds of millions of dollars for research. Market panic risks running out of money before its breakthrough technologies reach patients.
Analyst consensus forecast for the company's share price, the segment, and the market as a whole
Analyst consensus stock price forecast NMRA (Neumora Therapeutics)
Neumora Therapeutics is a biotech company using data science to develop next-generation drugs for the treatment of brain disorders (depression, schizophrenia). This chart shows the average target price. Analysts' forecasts are based on clinical data for its leading drugs and the potential of its technology platform.
&width=1500&height=450&colorIndex=78&filename=GURU_Markets_-_A-chart-showing-analyst-consensus-forecasts-for-the-expected-stock-price.-NMRA-Neumora-Therapeutics&v=1772655872908 "A chart showing analyst consensus forecasts for the expected stock price. NMRA (Neumora Therapeutics)")
The difference between the consensus estimate and the actual stock price NMRA (Neumora Therapeutics)
Neumora (NMRA) is a biotech company using AI and data analytics to reboot R&D for treating brain disorders (depression, schizophrenia). This chart is a barometer of their R&D. It measures the gap between the price and the consensus target, reflecting the high potential analysts see in their technology-driven approach to complex neuroscience.
&width=1500&height=450&colorIndex=79&filename=GURU_Markets_-_A-chart-showing-the-difference-between-the-consensus-forecast-and-the-actual-stock-price.-NMRA-Neumora-Therapeutics&v=1772655872916 "A chart showing the difference between the consensus forecast and the actual stock price. NMRA (Neumora Therapeutics)")
Analyst consensus forecast for stock prices by market segment - Neuro
Neumora Therapeutics is a biotech company using AI and big data to discover new drugs for complex brain disorders (depression, schizophrenia). This chart shows analysts' overall expectations for the neuroscience sector. It reflects whether experts believe AI can "hack" psychiatry.
Analysts' consensus forecast for the overall market share price
Neumora Therapeutics is a biotech company using big data and AI to develop precision treatments for brain diseases. This chart shows the overall risk appetite. For Neumora, which operates in the complex field of neuroscience, overall market optimism (the rising chart) is critical to funding their high-tech approach to R&D.
AKIMA index of the company, segment and market as a whole
AKiMA Company Index Neumora Therapeutics
Neumora Therapeutics is a next-generation biotech company focused on precision medicine for brain diseases. They use data analytics to find the right patients for their targeted drugs. This chart is a clear indicator of faith in their R&D platform. It reflects the market's appreciation of their clinical pipeline and their big-data approach to neuroscience.
AKIMA Market Segment Index - Neuro
Neumora Therapeutics is a company using big data and AI to develop new treatments for brain diseases. This chart shows the average index for the neuroscience segment. It provides investors with a benchmark for how Neumora's high-tech approach to R&D compares to the sector average among companies pursuing breakthroughs in neuroscience.
The AKIM Index for the overall market
Neumora is a biotech company using precision medicine and data to develop treatments for brain disorders (depression, schizophrenia). This chart, reflecting the market average, provides a macro backdrop. It helps assess how this ambitious neuroscience venture stacks up against the backdrop of overall economic trends and interest in the central nervous system.
